4BASEBIO PLC (88Q.DE) Stock Price, Forecast & Analysis

Europe • Frankfurt Stock Exchange • FRA:88Q • GB00BMCLYF79

6.3 EUR
-0.25 (-3.82%)
Last: Jan 26, 2026, 07:00 PM

88Q.DE Key Statistics, Chart & Performance

Key Statistics
Market Cap97.90M
Revenue(TTM)1.78M
Net Income(TTM)-14.41M
Shares15.54M
Float6.03M
52 Week High16.3
52 Week Low6.2
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)-1.15
PEN/A
Fwd PEN/A
Earnings (Next)05-25
IPO2021-02-17
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
88Q.DE short term performance overview.The bars show the price performance of 88Q.DE in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -10 -20 -30 -40 -50

88Q.DE long term performance overview.The bars show the price performance of 88Q.DE in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60

The current stock price of 88Q.DE is 6.3 EUR. In the past month the price decreased by -30%. In the past year, price decreased by -61.11%.

4BASEBIO PLC / 88Q Daily stock chart

88Q.DE Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

88Q.DE Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to 88Q.DE. While 88Q.DE seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

88Q.DE Financial Highlights

Over the last trailing twelve months 88Q.DE reported a non-GAAP Earnings per Share(EPS) of -1.15. The EPS decreased by -26.52% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -39.08%
ROE -75.9%
Debt/Equity 0.81
Chartmill High Growth Momentum
EPS Q2Q%-11.8%
Sales Q2Q%257.93%
EPS 1Y (TTM)-26.52%
Revenue 1Y (TTM)198.49%

88Q.DE Forecast & Estimates

9 analysts have analysed 88Q.DE and the average price target is 20.57 EUR. This implies a price increase of 226.55% is expected in the next year compared to the current price of 6.3.

For the next year, analysts expect an EPS growth of -34.32% and a revenue growth 50% for 88Q.DE


Analysts
Analysts84.44
Price Target20.57 (226.51%)
EPS Next Y-34.32%
Revenue Next Year50%

88Q.DE Ownership

Ownership
Inst Owners13.48%
Ins Owners10.95%
Short Float %N/A
Short RatioN/A

About 88Q.DE

Company Profile

88Q logo image 4basebio Plc is a biotechnology company, which engages in the business of developing advanced therapy medicinal products through synthetic DNA products and non-viral, cell targeting nucleic acid delivery platforms. The firm is focused on the development of advanced therapy medicinal products (ATMPs) through its synthetic Deoxyribonucleic acid (DNA) products and non-viral, cell-targeting nucleic acid delivery platform. The firm offers application-specific DNA constructs tailored to the diverse needs of gene therapies, genome editing, mRNA production, and DNA vaccines. Its synthetic DNA is produced via an enzymatic, cell-free manufacturing process. The company utilizes a technology for primer-free DNA amplification called TruePrime, which enables high-yield and quality DNA production. By combining two enzymes, Trueprime technology achieves isothermal multiple displacement DNA amplification in a continuous cell-free process with high fidelity. The firm offers application-specific synthetic DNA solutions across mRNA vaccines and therapies, viral vectors, gene editing, DNA vaccines and non-viral delivery.

Company Info

4BASEBIO PLC

25 Norman Way, Over

CAMBRIDGE GB

Employees: 0

88Q Company Website

88Q Investor Relations

Phone: 441223967943

4BASEBIO PLC / 88Q.DE FAQ

Can you describe the business of 4BASEBIO PLC?

4basebio Plc is a biotechnology company, which engages in the business of developing advanced therapy medicinal products through synthetic DNA products and non-viral, cell targeting nucleic acid delivery platforms. The firm is focused on the development of advanced therapy medicinal products (ATMPs) through its synthetic Deoxyribonucleic acid (DNA) products and non-viral, cell-targeting nucleic acid delivery platform. The firm offers application-specific DNA constructs tailored to the diverse needs of gene therapies, genome editing, mRNA production, and DNA vaccines. Its synthetic DNA is produced via an enzymatic, cell-free manufacturing process. The company utilizes a technology for primer-free DNA amplification called TruePrime, which enables high-yield and quality DNA production. By combining two enzymes, Trueprime technology achieves isothermal multiple displacement DNA amplification in a continuous cell-free process with high fidelity. The firm offers application-specific synthetic DNA solutions across mRNA vaccines and therapies, viral vectors, gene editing, DNA vaccines and non-viral delivery.


Can you provide the latest stock price for 4BASEBIO PLC?

The current stock price of 88Q.DE is 6.3 EUR. The price decreased by -3.82% in the last trading session.


Does 4BASEBIO PLC pay dividends?

88Q.DE does not pay a dividend.


How is the ChartMill rating for 4BASEBIO PLC?

88Q.DE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


Should I buy 88Q stock?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on 88Q.DE.


Who owns 4BASEBIO PLC?

You can find the ownership structure of 4BASEBIO PLC (88Q.DE) on the Ownership tab.